Spectral Net Income from 2010 to 2026

EDT Stock  CAD 1.45  0.05  3.57%   
Spectral Med Net Loss yearly trend continues to be very stable with very little volatility. Net Loss is likely to grow to about -13.2 M this year. During the period from 2010 to 2026, Spectral Med Net Loss quarterly data regression pattern had range of 13.2 M and standard deviation of  4,034,289. View All Fundamentals
 
Net Loss  
First Reported
1992-06-30
Previous Quarter
-1.9 M
Current Value
-30.3 M
Quarterly Volatility
3.1 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Spectral Med financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Spectral Med's main balance sheet or income statement drivers, such as Depreciation And Amortization of 214.6 K, Interest Expense of 3 M or Selling General Administrative of 7.3 M, as well as many indicators such as Price To Sales Ratio of 46.4, Dividend Yield of 0.36 or Days Sales Outstanding of 97.91. Spectral financial statements analysis is a perfect complement when working with Spectral Med Valuation or Volatility modules.
  
This module can also supplement various Spectral Med Technical models . Check out the analysis of Spectral Med Correlation against competitors.

Latest Spectral Med's Net Income Growth Pattern

Below is the plot of the Net Income of Spectral Med over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Spectral Med financial statement analysis. It represents the amount of money remaining after all of Spectral Med operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Spectral Med's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Spectral Med's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (15.39 M)10 Years Trend
Slightly volatile
   Net Income   
       Timeline  

Spectral Net Income Regression Statistics

Arithmetic Mean(9,271,265)
Coefficient Of Variation(43.51)
Mean Deviation3,106,603
Median(9,492,000)
Standard Deviation4,034,289
Sample Variance16.3T
Range13.2M
R-Value(0.60)
Mean Square Error11.1T
R-Squared0.36
Significance0.01
Slope(481,229)
Total Sum of Squares260.4T

Spectral Net Income History

2026-13.2 M
2025-13.9 M
2024-15.4 M
2023-15.7 M
2022-11.3 M
2021-8.8 M
2020-9.1 M

About Spectral Med Financial Statements

Spectral Med investors utilize fundamental indicators, such as Net Income, to predict how Spectral Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Loss-13.9 M-13.2 M
Net Loss-13.9 M-14.5 M
Net Loss-13.9 M-14.6 M
Net Loss(0.05)(0.05)
Net Income Per E B T 1.15  1.34 

Pair Trading with Spectral Med

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Spectral Med position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Spectral Med will appreciate offsetting losses from the drop in the long position's value.

Moving against Spectral Stock

  0.66KTO K2 GoldPairCorr
  0.61BRK Berkshire Hathaway CDRPairCorr
  0.57FFH-PI Fairfax FinancialPairCorr
  0.57AX-UN Artis Real EstatePairCorr
  0.47FFH Fairfax FinancialPairCorr
The ability to find closely correlated positions to Spectral Med could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Spectral Med when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Spectral Med - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Spectral Med to buy it.
The correlation of Spectral Med is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Spectral Med moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Spectral Med moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Spectral Med can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Other Information on Investing in Spectral Stock

Spectral Med financial ratios help investors to determine whether Spectral Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Spectral with respect to the benefits of owning Spectral Med security.